AGC Biologics announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO's contract development and manufacturing services. By using GORE and AGC Biologics, biopharmaceutical companies can improve downstream purification processes through increased productivity of the Protein A step, enabling a full single-use downstream process, which can eliminate column bioburden from storage, reduce manufacturing footprint, and help lower costs for clinical manufacturing and select scale commercial manufacturing. The collaboration includes the family of GORE® Protein Capture Devices with Protein A, which improves productivity in Protein A affinity purification, and provides high binding capacity at short residence times, alongside AGC Biologics' mAb-based CDMO services. The joint offering from Gore and AGC Biologics is available across various sites in the AGC Biologics' network.